Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01380769 | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT00915005 |
| completed |
| Phase 2 |
| 275 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| May 26, 2020 |
| clinicaltrials |
| NCT03472053 | A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | BioMarck Pharmaceuticals, Ltd.INDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT00806286 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 111 | Daiichi SankyoINDUSTRY | 4 | May 13, 2020 | clinicaltrials |
| NCT01671332 | Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 80 | University of Wisconsin, MadisonOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00271505 | Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT02221739 | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 39 | NYU Langone HealthOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02848651 | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer(B-F1RST) | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY | 17 | Apr 21, 2020 | clinicaltrials |
| NCT03499834 | A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy(IVY03) | completed | Phase 2 | 26 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02573506 | Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer | completed | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00137800 | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01773109 | Etirinotecan Pegol (NKTR-102) in NSCLC | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT03652857 | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 91 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03155009 | A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer(ATALK) | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01933347 | Third-line Treatment of Gefitinib in NSCLC Patients | completed | Phase 2 | 46 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00200395 | OSI-774 (Erlotinib, Tarceva) in Elderly Patients | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | completed | Phase 2 | 31 | Golden Biotechnology CorporationINDUSTRY | 2 | Dec 26, 2019 | clinicaltrials |
| NCT01813734 | Ponatinib in Advanced NSCLC w/ RET Translocations | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Dec 24, 2019 | clinicaltrials |
| NCT00137839 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | completed | Phase 2 | 84 | Pasi A. Janne, MD, PhDOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 0 | Dec 13, 2019 | clinicaltrials |
| NCT03129256 | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer(EASE) | completed | Phase 2 | 52 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00563784 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00582634 | Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer | completed | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00274443 | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | completed | Phase 2 | 250 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00771953 | 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | completed | Phase 2 | 109 | University of Maryland, BaltimoreOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00647426 | Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | completed | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01165021 | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT00775307 | Adjuvant Pazopanib in Stage I NSCLC | completed | Phase 2 / Phase 3 | 142 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01281124 | Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT00349089 | Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy | completed | Phase 2 | 132 | Thoraxklinik-Heidelberg gGmbHOTHER | 3 | Sep 19, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2020source: clinicaltrials